|
|
Post by sayhey24 on May 17, 2022 14:50:00 GMT -5
Immediate new revenue stream via V-Go and with it MannKind will have over 10000 patients on MannKind branded products with this new acquisition. The good news is we will be making money off of this immediately and be able to adequately grow the V-Go user population. I have full confidence we will see a clean FDA label with Tyvaso DPI and the way Mike talked about it, possibly an Afrezza label change concerning the Black Box Warning regarding COPD (since zero COPD patients have experienced bronchospasm). Good things headed our way! Mango - did Mike say we are going to be making money from V-Go immediately, as in it will be profitable? I missed his talk. I am hoping for the clean Tyvaso DPI label but I would not be surprised if Martine caved on some of the wording to get it approved. I hope I am wrong but expect approval soon. OK - the talk is still out there and I just listened - "cash flow is going to be fine". This translates to me that V-Go is going to lose money and we now have 15 more mouths to feed who have zero understanding of afrezza. From Mike's comments he is talking about it as a T2 device and no discussion transitioning into the T1 world. He is hoping it will work out - me too. Selling insulin as insulin into the T2 market is the reason afrezza has not sold. Doing the same thing over and over may not be the best thing. |
|
|
|
Post by cjm18 on May 17, 2022 15:05:51 GMT -5
Chat is up.
ABC trial is small
But bigger trial is option.
Peds trial goal is change soc
250k population to help but can still help 18-24 yr olds.
Vgo is 65% type 2 Medicare. Good?
Afrezza doesn’t have good Medicare coverage so little overlap?
Acquired 15 vgo reps that make up 60% of units.
Sales were falling.
Confident fdkp does not cause bronchospasm but no talk of trying to get rid of black box warning.
Tyvaso indications for copd and ipf will be over the years. 10x volume.
Don’t need 60m loan.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2022 15:40:35 GMT -5
Chat is up. ABC trial is small But bigger trial is option. Peds trial goal is change soc 250k population to help but can still help 18-24 yr olds. Vgo is 65% type 2 Medicare. Good? Afrezza doesn’t have good Medicare coverage so little overlap? Acquired 15 vgo reps that make up 60% of units. Sales were falling. Confident fdkp does not cause bronchospasm but no talk of trying to get rid of black box warning. Tyvaso indications for copd and ipf will be over the years. 10x volume. Don’t need 60m loan. I'm pretty sure Mike is hoping the BB warning is lifted. It doesn't make much sense if DPI avoids the same warning while it's treating a lung disease. (seems like a no brainer) Mike says NOW he doesn't need the $60M LOC from Mid Cap. Trust me...that will change. Mike will exercise the option and take the money. There's a chance Mid Cap could withdraw or change the terms as interest rates rise. Mike will bank the money and keep the favorable terms. Yes there's a deal in place but it could change. I'm not crazy about VGO acquisition but I will support Mike's decision. I hope their R&D Engineers can modernize the device. Looks pretty ARCANE to me. If they could add a bluetooth/cgm/algorithm and give T2's the ability to release the insulin via their iphone? That could be a game changer. Overall the Fireside Chat was Excellent. Mike gave good information and set good expectations (3 new revenue streams) coming this month and next. |
|
|
|
Post by beardawg on May 17, 2022 15:43:24 GMT -5
Mike says mnkd is working on 3 year Afrezza expiration for Biomm. Does anyone know more about this? He said it was completed today/yesterday for the US and they are working on the same for Brazil/Biomm. |
|
|
|
Post by mango on May 17, 2022 16:36:37 GMT -5
Immediate new revenue stream via V-Go and with it MannKind will have over 10000 patients on MannKind branded products with this new acquisition. The good news is we will be making money off of this immediately and be able to adequately grow the V-Go user population. I have full confidence we will see a clean FDA label with Tyvaso DPI and the way Mike talked about it, possibly an Afrezza label change concerning the Black Box Warning regarding COPD (since zero COPD patients have experienced bronchospasm). Good things headed our way! Mango - did Mike say we are going to be making money from V-Go immediately, as in it will be profitable? I missed his talk. I am hoping for the clean Tyvaso DPI label but I would not be surprised if Martine caved on some of the wording to get it approved. I hope I am wrong but expect approval soon. I plan relistening this afternoon but from what I heard I believe he said they will start selling it later this month or the next, so yeah, almost immediately. There is already patients established on it and we got 16 of the the top V-Go sales guys. My guess is V-Go will be rebranded soon. This also opens the doors to more potential providers and patients for Afrezza. Like someone else said, you always get those messages on Amazon when you buy something, “Since you purchased this, you might be interested in this too.” |
|
|
|
Post by porkini on May 17, 2022 17:18:18 GMT -5
Chat is up. ABC trial is small But bigger trial is option. Peds trial goal is change soc 250k population to help but can still help 18-24 yr olds. Vgo is 65% type 2 Medicare. Good? Afrezza doesn’t have good Medicare coverage so little overlap? Acquired 15 vgo reps that make up 60% of units. Sales were falling. Confident fdkp does not cause bronchospasm but no talk of trying to get rid of black box warning. Tyvaso indications for copd and ipf will be over the years. 10x volume. Don’t need 60m loan. Forget something? Help for your post: www.veracast.com/webcasts/rbc/healthcare2022/97126w.cfm |
|
|
|
Post by porkini on May 17, 2022 17:24:22 GMT -5
Mango - did Mike say we are going to be making money from V-Go immediately, as in it will be profitable? I missed his talk. I am hoping for the clean Tyvaso DPI label but I would not be surprised if Martine caved on some of the wording to get it approved. I hope I am wrong but expect approval soon. OK - the talk is still out there and I just listened - "cash flow is going to be fine". This translates to me that V-Go is going to lose money and we now have 15 more mouths to feed who have zero understanding of afrezza. From Mike's comments he is talking about it as a T2 device and no discussion transitioning into the T1 world. He is hoping it will work out - me too. Selling insulin as insulin into the T2 market is the reason afrezza has not sold. Doing the same thing over and over may not be the best thing. Surely not this - www.cbs.com/shows/the_talk/  Hoping that you also refer to this: www.veracast.com/webcasts/rbc/healthcare2022/97126w.cfm |
|
|
|
Post by agedhippie on May 17, 2022 17:50:28 GMT -5
I'm not crazy about VGO acquisition but I will support Mike's decision. I hope their R&D Engineers can modernize the device. Looks pretty ARCANE to me. If they could add a bluetooth/cgm/algorithm and give T2's the ability to release the insulin via their iphone? That could be a game changer. The V-Go is purely mechanical which is why it only has three dose rates (20, 30, or 40u). The rate is set by the strength of the spring. The plus side is that it doesn't count as durable medical equipment like a conventional pump. It competes with traditional basal insulin, but with the twist that it can dispense an extra 2u bolus if you push the button on the pump. You still have to buy RAA and fill the device. Why exactly I would swap Tresiba for this if I was on Afrezza is unclear to me.  The history is that Zealand Pharma bought V-Go out of the Valeritas bankruptcy (Valeritas were the original owners going back to 2012). Looking at Zealand and Valeritas filings I think that the V-Go is cash-flow positive and generates a gross profit of around $15M. Once SGA is applied that was negative, but Mannkind should be able to clean that up enough to get cash-flow positive overall. |
|
|
|
Post by sayhey24 on May 17, 2022 20:08:13 GMT -5
Aged - the reason you would swap Tresiba for this if you were on afrezza is to solve the sleeping TIR period you talk about. I don't think buying V-Go makes much sense unless Dave Kendall thinks they can sell it into the T1 market which would require a trial. The trial would need to combine this patch with afrezza.
However, on the "talk" today Mike made no mention of that so I am at a loss. I never see this as a money maker. Unless Mike has a secret plan he did not disclose today he should be trying to figure out how to get out of this deal.
|
|
|
|
Post by techman on May 17, 2022 20:20:23 GMT -5
Smoke and mirrors again? What is the definition of stupidity? You keep doing the same thing but expect different results.
|
|
|
|
Post by sayhey24 on May 17, 2022 20:26:22 GMT -5
Smoke and mirrors again? What is the definition of stupidity? You keep doing the same thing but expect different results. Explain? What same thing? |
|
|
|
Post by peppy on May 17, 2022 20:38:32 GMT -5
I'm not crazy about VGO acquisition but I will support Mike's decision. I hope their R&D Engineers can modernize the device. Looks pretty ARCANE to me. If they could add a bluetooth/cgm/algorithm and give T2's the ability to release the insulin via their iphone? That could be a game changer. The V-Go is purely mechanical which is why it only has three dose rates (20, 30, or 40u). The rate is set by the strength of the spring. The plus side is that it doesn't count as durable medical equipment like a conventional pump. It competes with traditional basal insulin, but with the twist that it can dispense an extra 2u bolus if you push the button on the pump. You still have to buy RAA and fill the device. Why exactly I would swap Tresiba for this if I was on Afrezza is unclear to me.The history is that Zealand Pharma bought V-Go out of the Valeritas bankruptcy (Valeritas were the original owners going back to 2012). Looking at Zealand and Valeritas filings I think that the V-Go is cash-flow positive and generates a gross profit of around $15M. Once SGA is applied that was negative, but Mannkind should be able to clean that up enough to get cash-flow positive overall. I am trying to think it through as well. What I come up with is it is a wide world. In some parts of the world vials with basal are still sold? In some parts of the world tresiba pens are not in the healthcare coverage plans? Brazil? India? Refillable, self adhesive, no wires, pump. Some people still buy vials. Or Mike is a spender at heart and Kendall talked him into it. Or hopefully Binder was in on the revenue side. |
|
|
|
Post by sayhey24 on May 17, 2022 21:01:13 GMT -5
Peppy - I am hoping for a secret plan which Dave Kendall has to help MNKD. Then again Dave left us flat after promising to get afrezza in the ADA T2 SoC. I am hoping Dave feels he owes MNKD and now that Mounjaro is approved he thinks he can help. I am hoping Dave is not screwing MNKD again.
Hope springs eternal with V-Go.
|
|
|
|
Post by peppy on May 17, 2022 21:09:14 GMT -5
Peppy - I am hoping for a secret plan which Dave Kendall has to help MNKD. Then again Dave left us flat after promising to get afrezza in the ADA T2 SoC. I am hoping Dave feels he owes MNKD and now that Mounjaro is approved he thinks he can help. I am hoping Dave is not screwing MNKD again. Hope springs eternal with V-Go. Here is what I really think. It is a money and numbers game. They are not letting us in. We are too expensive as we are now. /photo/1 I follow politics pretty closely. Scott from florida, has a plan to phase out social security and medicare over the next 5 years. Insurance isn't paying. perhaps that's why Mike bought V-Go. Vials of generic basal at Walmart for $25 bucks.  |
|
|
|
Post by porkini on May 17, 2022 21:09:46 GMT -5
Peppy - I am hoping for a secret plan which Dave Kendall has to help MNKD. Then again Dave left us flat after promising to get afrezza in the ADA T2 SoC. I am hoping Dave feels he owes MNKD and now that Mounjaro is approved he thinks he can help. I am hoping Dave is not screwing MNKD again. Hope springs eternal with V-Go. Sorry, but I don't see where Kendall "screwed" MNKD. He may have made a "flip" comment about ease of job, but I'm not certain there is evidence he "screwed" MNKD. |
|
